DNA vaccines: prime time is now.

DNA vaccines: prime time is now.
Curr Opin Immunol. 2020 Apr 04;65:21-27
Authors: Gary EN, Weiner DB
Abstract
Recently newer synthetic DNA vaccines have been rapidly advanced to clinical study and have demonstrated an impressive degree of immune potency and tolerability. Improvements in DNA delivery over prior needle and syringe approaches include jet delivery, gene gun delivery, among others. Among the most effective of these new delivery methods, advanced electroporation (EP), combined with other advances, induces robust humoral and cellular immunity in both preventative as well as therapeutic studies. Advancements in the design of the DNA inserts include leader sequence changes, RNA and codon optimizations, improved insert designs, increased concentrations of DNA, and skin delivery, appear to complement newer delivery strategies. These advances also provide a framework for the in vivo production of synthetic DNA biologics. In this review, we focus on recent studies of synthetic DNA vaccines in the clinic for the prevention or treatment of infectious diseases with a focus on adaptive electroporation for delivery, and briefly summarize novel preclinical data advancing the in vivo delivery of DNA-encoded antibody-like biologics.
PMID: 32259744 [PubMed - as supplied by publisher]

Source: Current Opinion in Immunology - April 3, 2020 Category: Allergy & Immunology Authors: Gary EN, Weiner DB Tags: Curr Opin Immunol Source Type: research